BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38569135)

  • 1. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both
    Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
    J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
    Mu J; Sun P; Ma Z; Sun P
    J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer.
    Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
    Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
    Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
    Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
    Liu J; Duan Z; Guo W; Zeng L; Wu Y; Chen Y; Tai F; Wang Y; Lin Y; Zhang Q; He Y; Deng J; Stewart RL; Wang C; Lin PC; Ghaffari S; Evers BM; Liu S; Zhou MM; Zhou BP; Shi J
    Nat Commun; 2018 Dec; 9(1):5200. PubMed ID: 30518851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.
    Xiao RQ; Ran T; Huang QX; Hu GS; Fan DM; Yi J; Liu W
    Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2200753119. PubMed ID: 35969736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
    Mqoco T; Stander A; Engelbrecht AM; Joubert AM
    Biomed Res Int; 2019; 2019():1850462. PubMed ID: 31886177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.